Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 8 mg injection every 2 weeks
EFPE_SC_8MG_Q2W
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.70 (-12.28 to 7.21) | 0.42 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.81 (-14.06 to 1.88) | 0.44 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 14.23 (1.42 to 61.91) | 0.60 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.16 (0.76 to 26.59) | 0.38 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.88 (0.35 to 46.27) | 0.25 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.41 (0.78 to 8.18) | 0.43 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.21 (2.14 to 8.89) | 0.41 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.66 (1.69 to 14.37) | 0.46 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.36 (0.58 to 3.30) | 0.64 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.30 (0.74 to 7.48) | 0.45 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.93 (1.12 to 26.43) | 0.29 |